Efficacy and safety of cerivastatin, a novel potent HMG-CoA reductase inhibitor, in primary hypercholesterolaemia: A comparative study

被引：0
|
作者：
Leiter, LA [1 ]
机构：
[1] ST MICHAELS HOSP,TORONTO,ON M5B 1W8,CANADA
来源：
ATHEROSCLEROSIS | 1997年 / 134卷 / 1-2期
关键词：
D O I：
10.1016/S0021-9150(97)88696-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：128 / 129
页数：2
相关论文
共 50 条
  • [11] Cerivastatin: the low-dose HMG-COA reductase inhibitor
    Tikkanen, MJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (01) : 161 - 166
  • [12] Cerivastatin approval expands HMG-CoA reductase inhibitor choices
    不详
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (16) : 1793 - 1793
  • [13] Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
    Muck, W
    Ritter, W
    Ochmann, K
    Unger, S
    Ahr, G
    Wingender, W
    Kuhlmann, J
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (06) : 255 - 260
  • [14] Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor
    Kajinami, K
    Takekoshi, N
    Saito, Y
    CARDIOVASCULAR DRUG REVIEWS, 2003, 21 (03): : 199 - 215
  • [15] COMPARATIVE-EVALUATION OF THE SAFETY AND EFFICACY OF HMG-COA REDUCTASE INHIBITOR MONOTHERAPY IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA
    HSU, I
    SPINLER, SA
    JOHNSON, NE
    ANNALS OF PHARMACOTHERAPY, 1995, 29 (7-8) : 743 - 759
  • [16] Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers
    Mazzu, A
    Lettieri, J
    Kaiser, L
    Mullican, W
    Heller, AH
    JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (08): : 715 - 719
  • [17] SYNTHESIS OF A NOVEL HMG-COA REDUCTASE INHIBITOR
    BAADER, E
    BARTMANN, W
    BECK, G
    BERGMANN, A
    JENDRALLA, H
    KESSELER, K
    WESS, G
    SCHUBERT, W
    GRANZER, E
    VONKEREKJARTO, B
    KRAUSE, R
    TETRAHEDRON LETTERS, 1988, 29 (08) : 929 - 930
  • [18] A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia
    Sasaki, J
    Arakawa, K
    Yamamoto, K
    Kobori, S
    Ageta, M
    Kono, S
    CLINICAL THERAPEUTICS, 1998, 20 (03) : 539 - 548
  • [19] The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium
    Berkels, R
    Nouri, SK
    Taubert, D
    Bartels, H
    Roesen, P
    Roesen, R
    Klaus, WF
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (03) : 356 - 363
  • [20] Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
    Mück, W
    Unger, S
    Kawano, K
    Ahr, G
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 583 - 590
12345